Characteristic |
Schober 2001 |
Tunbridge 1989 |
Zinman 1999 |
Rossetti 2003 |
Vague 2003 |
Intervention 1 (I1) / intervention 2 (I2) / control 1 (C1) |
I1: Glargine + HI
C1: NPH + HI |
I1: Ultralente + HI
C1: Lente + HI |
I1: Ultralente + Lispro
C1: NPH + Lispro |
I1: Glargine dinnertime + Lispro
I2: Glargine bedtime + Lispro
C: NPH + Lispro |
I1: Detemir + Aspart
C: NPH + Aspart |
[n] (I1/ I2 / C1 / total) |
174/175/349 |
66/66/66 |
87/91/178 |
17/17/17/54 |
301/146/447 |
Sex (male) [n,%] |
? |
37, 56% |
41, 47% / 35, 38* |
9, 52% / 8, 47% / 10, 58% |
162, 53% / 74, 50.7% |
Age [years] mean (SD) |
11.8 (2) / 11.5 (2) |
38 (range 18‐62) |
35 (1) / 35 (1) |
32 (3) / 31.3 (3.4) / 34 (3.1) |
38.9 (13.3) / 41.8 (14.2) |
Ethnic groups [%] |
? |
? |
? |
? |
? |
Duration of disease [years] mean (SD) |
? |
14 (range 3‐30) |
13.6 (0.8) / 16.1 (1.1) |
13.1 (1.9) / 12.9 (2.3) / 14.8 (2.3) |
17.1 (9.9) / 17.4 (11) |
Body mass index [kg/m2] mean (SD)
Weight [kg] mean (SD) |
18.8 (2) / 18.9 ( 2) |
25.3 (range 18.6‐33.4)
Kg: 73.0 (range 45.6‐99.0) |
25 (1) / 25 (1)
Kg: 74 (1) / 75 (1) |
23.1 (0.8) / 22.9 (1) / 23.2 (0.9) |
24.5 (3.2) / 24.6 (3.4)
Kg: 71.5 (11.9) / 71.2 (11.5) |
Pharmaco‐naive patients [n,%] |
0 / 0 |
0 / 0 |
0 / 0 |
0/0/0 |
0/0/0 |
HbA1c [%] mean (SD) |
? (all <12%) |
9.0 (range 6.6‐11.4) |
8.2 (0.1) / 8.2 (0.1) |
6.9 (0.1) / 6.8 (0.2) / 7 (0.2) |
8.18 (1.14) / 8.11 (1.12) |
Fasting blood glucose |
? |
? |
? |
? |
? |
Fasting plasma glucose |
? |
? |
? |
? |
11.6 (5.21) / 11.6 (5.27) |
Basal insulin dose (IU/day) |
? |
? |
? |
? |
27.4 (12.5) / 25.2 (13.7) |
Bolus insulin dose (IU/day) |
? |
? |
? |
? |
30.9 (15.5) / 29.6 (15.8) |
Clinically different baseline characteristics (Y/N) |
N |
NA |
NA |
N |
N |
Notes |
letter publication |
crossover trial |
|
|
|
Symbols & abbreviations: Y = yes; N = no; ? = unclear
I = intervention; C = control |
|
|
|
|
|